Search results
Results from the WOW.Com Content Network
Intravascular hemolysis describes hemolysis that happens mainly inside the vasculature. [1] As a result, the contents of the red blood cell are released into the general circulation, leading to hemoglobinemia [ 2 ] and increasing the risk of ensuing hyperbilirubinemia .
Hemoglobinuria is a condition in which the oxygen transport protein hemoglobin is found in abnormally high concentrations in the urine. [1] The condition is caused by excessive intravascular hemolysis, in which large numbers of red blood cells (RBCs) are destroyed, thereby releasing free hemoglobin into the plasma. [2]
Paroxysmal cold hemoglobinuria (PCH) or Donath–Landsteiner hemolytic anemia (DLHA) is an autoimmune hemolytic anemia featured by complement-mediated intravascular hemolysis after cold exposure. [1] It can present as an acute non-recurrent postinfectious event in children, or chronic relapsing episodes in adults with hematological malignancies ...
Danicopan, sold under the brand name Voydeya, is a medication used for the treatment of paroxysmal nocturnal hemoglobinuria. It is a complement inhibitor which reversibly binds to factor D to prevent alternative pathway-mediated hemolysis and deposition of complement C3 proteins on red blood cells. The most common side effects include fever, headache, increased levels of liver enzymes (a sign ...
Acquired hemolytic anemia is also encountered in burns and as a result of certain infections (e.g. malaria). [15] [18] Paroxysmal nocturnal hemoglobinuria (PNH), sometimes referred to as Marchiafava-Micheli syndrome, is a rare, acquired, potentially life-threatening disease of the blood characterized by complement-induced intravascular ...
Hemosiderinuria (syn. haemosiderinuria) is the presence of hemosiderin in urine. [1] It is often the result of chronic intravascular hemolysis, in which hemoglobin is released from red blood cells into the bloodstream in excess of the binding capacity of haptoglobin.
A 2014 Canadian study calculated the cost per life-year-gained with treatment as CAN$4.62 million (US$4,571,564) and cost per quality-adjusted-life-year as CAN$2.13 million (US$2,112,398)."The incremental cost per life year and per QALY gained is CAN$4.62 million and CAN$2.13 million, respectively.
Hemolytic anemia* is a type of regenerative anemia found in dogs characterized by destruction of the red blood cell. The most important type is immune-mediated hemolytic anemia, which can be a primary disease or secondary to cancer, infection, drugs, or vaccinations. Antibodies are present on the cell surface, leading to lysis and severe anemia.